Current Research Studies
Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents >= 6 to < 18 years of age
Rimegepant 312
- Phase: III
- Clinicaltrials.gov ID: NCT04743141
What is the goal of the study?
To evaluate the safety and tolerability of rimegepant in children and adolescents (age >= 6 to < 18 years of age).
Who can participate in the study?
Please contact the study team listed below to learn more.
Study Team:
- PI (Study Doctor): Heidi Blume
- Study Team Member: Mikaela Morales, [email protected]